Role of angiotensin II type 1 receptor on retinal vascular leakage in a rat oxygen-induced retinopathy model

Ophthalmic Research

Volumn 41, Issue 4, 2009, Pages 210-215

  Nakamura, Hiroaki ^a   Yamazaki, Mami ^a   Ohyama, Takao ^a   Inoue, Tatsuya ^a   Arakawa, Naohisa ^a   Domon, Yuki ^a   Yokoyama, Tomihisa ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Angiotensin type 1 receptor; Hypoxia induced hyperpermeability; Oxygen induced retinopathy; Vascular endothelial growth factor

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; FLUORESCEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OLMESARTAN; OXYGEN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOXIA; IMMUNOBLOTTING; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA BLOOD VESSEL; RETINAL VASCULAR HYPERPERMEABILITY; RETINOPATHY; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CAPILLARY PERMEABILITY; HYPOXIA-INDUCIBLE FACTOR 1; IMIDAZOLES; INJECTIONS, SUBCUTANEOUS; ISCHEMIA; OXYGEN; PYRIDINES; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RETINAL DISEASES; RETINAL VESSELS; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOCONSTRICTOR AGENTS;

EID: 65649120479     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000217725     Document Type: Article

References (30)

1. Adamis AP: Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002;86:363-365.
2. Cunha Vaz JG: The blood-ocular barriers: past, present, and future. Doc Ophthalmol 1997;93:149-157.
3. do Carmo A, Ramos P, Reis A, Proença R, Cunha-Vaz JG: Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res 1998;67:569-575.
4. Moss SE, Klein R, Klein BE: The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003.
5. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K: The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996;74:819-825.
6. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-2413.
7. Zhang SX, Ma JX, Sima J, Chen Y, Hu MS, Ottlecz A, Lambrou GN: Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy. Am J Pathol 2005;166:313-321.
8. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
9. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450.
10. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613.
11. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA: Hypoxia-inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999;40:182-189.
12. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 2002;133:537-543.
13. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
14. Otani A, Takagi H, Suzuma K, Honda Y: Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998;82:619-628.
15. Otani A, Takagi H, Oh H, Suzuma K, Matsumura M, Ikeda E, Honda Y: Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 2000;41:1192-1199.
16. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000;43:1360-1367.
17. Sano H, Hosokawa K, Kidoya H, Takakura N: Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler Thromb Vasc Biol 2006;26:2673-2680.
18. Zhang SX, Sima J, Shao C, Fant J, Chen Y, Rohrer B, Gao G, Ma JX: Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. Diabetologia 2004;47:124-131.
19. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP: VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-2162.
20. Yamashiro K, Tsujikawa A, Ishida S, Usui T, Kaji Y, Honda Y, Ogura Y, Adamis AP: Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol 2003;163:253-259.
21. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX: Pigment epithelium-derived factor (PEDF) is an endogenous anti-inflammatory factor. FASEB J 2006;20:323-325.
22. Kotch LE, Iyer NV, Laughner E, Semenza GL: Defective vascularization of HIF-1 alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 1999;209:254-267.
23. Mizukami Y, Fujiki K, Duerr EM, Gala M, Jo WS, Zhang X, Chung DC: Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006;281:13957-13963.
24. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, Skinner SL, Wilkinson-Berka JL: Retinal neovascularization is prevented by blockade of the reninangiotensin system. Hyper tension 2000;36:1099-1104.
25. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL: Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003;163:879-887.
26. Yokoyama T, Inoue T, Nakamura H, Arakawa N, Shimizu Y: An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, prevents mouse oxygen-induced retinopathy and VEGF-induced rabbit corneal neovascularization (E-abstract). Invest Ophthalmol Vis Sci 2004;45:1910.
27. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP: Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000;156:1733-1739.
28. Nagai N, Noda K, Urano T, Kubota Y, Shinoda H, Koto T, Shinoda K, Inoue M, Shiomi T, Ikeda E, Tsubota K, Suda T, Oike Y, Ishida S: Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005;46:1078-1084.
29. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-463.
30. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T: Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001;88:22-29.